-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Lung Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Lung Disease Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Relapsed Acute Myeloid Leukemia Drug Details: L-Annamycin...
-
Product Insights
Irritable Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Irritable Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Irritable Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Smoking Cessation – Drugs In Development, 2023
Global Markets Direct’s, ‘Smoking Cessation - Drugs In Development, 2023’, provides an overview of the Smoking Cessation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vitiligo – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitiligo - Drugs In Development, 2023’, provides an overview of the Vitiligo pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Restless Legs Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Restless Legs Syndrome - Drugs In Development, 2023’, provides an overview of the Restless Legs Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...